Urolithin A improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity
- 24 July 2025
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 393, 115395
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82473899)
- Natural Science Foundation of Shandong Province (ZR2022LSW025)
This publication has 35 references indexed in Scilit:
- Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functionsAlzheimer's & Dementia, 2024
- P-tau217 correlates with neurodegeneration in Alzheimer’s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathyNeuron, 2024
- Urolithin B Attenuates Cerebral Ischemia–reperfusion Injury by Modulating Nrf2-regulated Anti-oxidation in RatsNeuroscience, 2023
- Urolithin A Attenuates Diabetes‐Associated Cognitive Impairment by Ameliorating Intestinal Barrier Dysfunction via N‐glycan Biosynthesis PathwayMolecular Nutrition & Food Research, 2022
- A53T α-synuclein induces neurogenesis impairment and cognitive dysfunction in line M83 transgenic mice and reduces the proliferation of embryonic neural stem cellsBrain Research Bulletin, 2022
- Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson's disease modelNeuropharmacology, 2022
- Impact of the Natural Compound Urolithin A on Health, Disease, and AgingTrends in Molecular Medicine, 2021
- IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson’s diseaseNeuroToxicology, 2021
- Urolithin A ameliorates experimental autoimmune encephalomyelitis by targeting aryl hydrocarbon receptorEBioMedicine, 2021
- Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological studyMovement Disorders, 2008